This inventor holds 3 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Medimmune Limited. Active years: 2017-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2022
Title: Rasmus Jansson Lofmark: Innovator in Metabolic Disease Treatment
Introduction
Rasmus Jansson Lofmark is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of metabolic disease treatment, particularly in obesity management. With a total of 3 patents to his name, Lofmark is recognized for his innovative approaches to healthcare.
Latest Patents
Lofmark's latest patents include groundbreaking work on glucagon/GLP-1 agonists for the treatment of obesity. These disclosures provide GLP-1/glucagon agonist peptides aimed at addressing metabolic diseases, such as obesity. His research focuses on developing effective therapeutic options that can significantly improve patient outcomes.
Career Highlights
Lofmark is currently associated with MedImmune Limited, where he continues to advance his research in metabolic diseases. His work has garnered attention for its potential to revolutionize treatment methodologies in this critical area of healthcare.
Collaborations
Some of Lofmark's notable coworkers include Balaji Agoram and Madeleine Antonsson. Their collaborative efforts contribute to the innovative environment at MedImmune Limited, fostering advancements in medical research.
Conclusion
Rasmus Jansson Lofmark stands out as a key figure in the development of treatments for obesity and metabolic diseases. His patents and ongoing research reflect a commitment to improving health outcomes through innovation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile